SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
The SINGLE-AF clinical trial found that oral anticoagulants benefit patients with atrial fibrillation at intermediate risk of stroke. These direct oral anticoagulants reduced the risk of stroke in this lower-risk patient population.
Epilogue added 75d ago, after coverage quieted.
The brief
"SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke" is generating significant coverage in the Health category, with 12 articles from 9 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Seoul Economic Daily, Korea Biomedical Review, Medscape and News-Medical. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 71d ago.
Quick answers
Why is "SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate " trending?
Because 9 independent news sources published 12 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (12)
- Blood Thinners Cut Stroke Risk in Moderate-Risk Heart Patients Seoul Economic Daily · 78d ago
- [ESC 2026] SINGLE-AF study closes evidence gap on DOACs in intermediate-risk AF Korea Biomedical Review · 78d ago
- To Anticoagulate or Not in Intermediate-Risk AF: The SINGLE-AF Trial Medscape · 78d ago
- New findings do not support the use of edoxaban in AF patients after intracranial hemorrhage News-Medical · 78d ago
- ENRICH-AF: Edoxaban Increases Bleeding Without Reducing Stroke HCPLive · 78d ago
- People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, clinical trial finds Medical Xpress · 78d ago
- DOACs Benefit AF Patients With Intermediate Stroke Risk: SINGLE-AF TCTMD.com · 78d ago
- First Major Trial Win for Contemporary DOACs in Lower-Risk Afib MedPage Today · 78d ago
- SINGLE-AF: Oral Anticoagulants Reduce Risk of Stroke in Patients With AF HCPLive · 78d ago
- Oral anticoagulants benefit patients with atrial fibrillation at intermediate stroke risk News-Medical · 78d ago
- DOACs Benefit AF Patients With Intermediate Stroke Risk Medscape · 78d ago
- SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke American College of Cardiology · 78d ago
Topics
Related trends
Ultrahuman Now Offers On-Demand Heart Rhythm Scans
Ultrahuman expands its health tracking capabilities by introducing an on-demand heart rhythm scan feature for smart ring users.
New Canadian minimally invasive robotic procedure could revolutionize AFib treatment
St. Michael’s Hospital has completed Canada's first robotic hybrid procedure to treat atrial fibrillation, offering a new minimally invasive option for patients.
Menopause: ACOG Recommends Hormone Therapy for Hot Flashes and Mood
Menopause hormone therapy receives fresh medical attention and renewed support for addressing hot flashes and mood changes.
Optogenetic Therapy for Restoring Aspects of Visual Function
Recent scientific findings detail the use of optogenetic therapy and special goggles to restore limited vision in blind patients.
UCLA’s $5,000 T-Cell Therapy Could Upend Solid-Tumor Cancer Treatment
UCLA scientists have developed a method to convert cord blood into powerful T cells designed to fight solid-tumor cancers at a cost of $5,000.
Novartis Pauses Autoimmune Cell Therapy Studies After Deaths
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.